Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of JR-142 in pediatric growth hormone deficiency
jRCT2031210366Phase 2Active, not recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Nov 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of redalsomatropin alfa in growth hormone deficiency (GHD) (2 arms), sponsored by JCR Pharmaceuticals. Primary endpoint: Change in height SDS for chronological age from baseline. Started Nov 2021; status: active, not recruiting.
02
Drugs
redalsomatropin alfa
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on jRCT2031210366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210366.